AllSci News
Pilatus puts CD36-blocking “metabolic checkpoint” antibody into Phase I solid tumor study
Pilatus Biosciences has dosed the first patient in a Phase I clinical trial of PLT012, a humanized monoclonal antibody that blocks CD36-mediated…
Enodia swoops on troubled Kezar’s Sec61 pipeline
France-based Enodia Therapeutics and the San Francisco-based biotech Kezar Life Sciences, Inc. (NASDAQ: KZR) announced that Enodia has acquired Kezar’s preclinical assets…
Vertex hopeful on first-mover status for BAFF+APRIL povetacicept after Phase III data
Vertex Pharmaceuticals announced positive results from a pre-specified Week 36 interim analysis of the RAINIER Phase III trial evaluating povetacicept in adults…
Dianthus Therapeutics raises USD 400m via share offering
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company based in New York City and Waltham, Massachusetts, announced a proposed USD 400…
NewcelX, Eledon to pair stem cell therapy with CD40 mAb against type 1 diabetes
Zurich-based NewcelX Ltd. (Nasdaq: NCEL) and Irvine, California-based Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have entered a collaborative research agreement to evaluate a…
EC nods J&J’s PARPi combo Akeega for new BRCA prostate cancer indication
The European Commission has approved an expanded indication for Akeega (niraparib and abiraterone acetate), a dual action tablet developed by Johnson &…
Regeneron/Hansoh’s GLP-1/GIPr agonist shows 19% weight loss in China Phase III
Regeneron Pharmaceuticals announced that its licensing partner, China-based Hansoh Pharmaceutical Group, has reported positive Phase III results for olatorepatide, a dual GLP-1/GIP…
AbbVie’s amylin race entrant ABBV-295 delivers up to 9.8% weight loss in Phase I
AbbVie announced topline results from the multiple ascending dose portion of a Phase I study of ABBV-295, a long-acting amylin analog, in…
Roche reports Phase III miss for giredestrant in first-line breast cancer setting
Roche’s giredestrant misses primary endpoint in persevERA trial for ER-positive advanced breast cancer Roche announced that the Phase III persevERA Breast Cancer…
Servier’s USD 2.5b Day One Bio acquisition gives control of glioma drug Ojemda
Servier is moving to acquire US biotech Day One Biopharmaceuticals (Nasdaq: DAWN) for around USD 2.5 billion. The an all-cash transaction will…
Roche partner Zealand’s Phase II data for petrelintide shows placebo-like safety
Copenhagen-based Zealand Pharma announced positive petrelintide Phase II results from the ZUPREME-1 dose-finding trial, reporting up to 10.7% mean body weight reduction…
Erasca and Tango Therapeutics partner on ERAS-0015 and vopimetostat combination trial
US biopharma companies Erasca, Inc. and Tango Therapeutics entered a clinical trial collaboration and supply agreement to evaluate a combination of ERAS-0015,…
Alnylam looks to Tenaya for new RNAi cardiovascular target candidates in USD 1.2b deal
US-based biotechs Tenaya Therapeutics, Inc. (Nasdaq: TNYA) and Alnylam Pharmaceuticals (Nasdaq: ALNY) entered into a research collaboration agreement to discover and validate…
Theravance in crisis after Phase III ampreloxetine failure in MSA-related nOH
Theravance Biopharma announced that the Phase III CYPRESS study evaluating ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple…
Hutchmed advances ATTC platform with first-in-human trial of EGFR-targeted PI3K/PIKK conjugate
China-based biopharma HutchMed (Nasdaq/AIM:HCM;HKEX:13) announced the clinical debut of pipeline candidate HMPL-A580, an antibody-targeted therapy conjugate (ATTC) designed to deliver a PI3K/PIKK…
The AllSci Brief
Systematic R&D and deal news. Daily.